37.8 billion euros.
This is the turnover recorded in 2021 by the pharmaceutical group Sanofi.
An increase of 4.8% compared to last year for the company, which employs 100,000 people worldwide.
In addition, the group which published these results on Friday indicates that the net earnings per share of the activities (one of its preferred financial indicators), rose by nearly 12%, which is much more than expected.
On the strength of these figures, the laboratory announced that it would offer its shareholders a dividend of 3.33 euros, against 3.20 euros for the previous year, an increase of 4%.
Last year, the payment of dividends represented a total of just over 4 billion euros to its shareholders.
For 2022, Sanofi says it is confident, and again anticipates a solid increase, "in the lower double-digit range", he said in a press release.
What wipe the setback for Sanofi in the search for a vaccine against Covid-19.
The group was able to count on the sales of its star product Dupixent.
This drug, used against asthma and certain dermatitis, could eventually bring in more than 10 billion euros in sales per year.
Last year, it brought in 5.2 billion euros, an increase of almost 53% compared to 2020.
Politics
Jean Castex will announce “a massive reinvestment plan for Sanofi in France”
Economy
Sanofi sells its Strasbourg site to Novalix
Laboratory
Economy
Vaccine
Pharmaceutical industry
Sanofi
Health
0 comment
0 share
Share on Messenger
Share on Facebook
Share on Twitter
Share on Flipboard
Share on Pinterest
Share on Linkedin
Send by Mail
To safeguard
A fault ?
To print